Findings

What do systematic reviews say?

2 questions · 3 findings · 1 reviews · Kidney and Transplant

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 0 · 0%Moderate 1 · 33.3%High 0 · 0%

Loss of patency by 12 months · Dialysis vascular access outcomes in AVF patients with ESKD

Omega‐3 fatty acids showed no clear difference in loss of patency: compared with placebo (moderate certainty).

1 finding from 1 review

Loss of patency by 12 months · dialysis vascular access outcomes in AVG patients with ESKD

It is very uncertain whether omega‐3 fatty acids changes loss of patency by 6 months compared with placebo (very low certainty).

2 findings from 1 review

Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes only
RR 0.91 [0.36, 2.28]
2 studies · 41 participants
Very low
Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes only
RR 0.59 [0.27, 1.31]
2 studies · 220 participants
Very low